<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00646191</url>
  </required_header>
  <id_info>
    <org_study_id>M02-529</org_study_id>
    <nct_id>NCT00646191</nct_id>
  </id_info>
  <brief_title>Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis</brief_title>
  <official_title>Multicenter Extension Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Chronic
      Plaque Psoriasis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <primary_completion_date type="Actual">June 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Psoriasis Area and Severity Index</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Throughout Study Participation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Psoriasis Area and Severity Index</measure>
    <time_frame>Week 0, 4, 8, 12, 16, 20, 24, 32, 40 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DLQI, SF-36, Zung Depression Self-Rating Scale, EQ-5D, VAS</measure>
    <time_frame>Week 12, 24 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's Global Assessment</measure>
    <time_frame>Week 12, 16, 20, 24, 32, 40 and 48</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">137</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adalimumab</intervention_name>
    <description>40 mg eow through Week 12 followed by OL 40 mg eow through Week 48, permitted to escalate to weekly dosing upon relapse</description>
    <arm_group_label>A</arm_group_label>
    <other_name>ABT-D2E7</other_name>
    <other_name>Humira</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adalimumab</intervention_name>
    <description>40 mg weekly through Week 48 (OL Week 12 - 48)</description>
    <arm_group_label>B</arm_group_label>
    <other_name>ABT-D2E7</other_name>
    <other_name>Humira</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adalimumab</intervention_name>
    <description>80 mg W0, 40 mg eow through Week 12 followed by OL 40 mg eow through Week 48, permitted to escalate to weekly dosing upon relapse</description>
    <arm_group_label>C</arm_group_label>
    <other_name>ABT-D2E7</other_name>
    <other_name>Humira</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject completed prior PS study

        Exclusion Criteria:

          -  Subject has other active skin diseases

          -  Multiple concomitant therapy restrictions and/or washouts (topicals, UV, other
             systemic PS therapies)

          -  Poorly controlled medical conditions

          -  History of neurologic symptoms suggestive of central nervous system (CNS)
             demyelinating disease

          -  History of cancer or lymphoproliferative disease

          -  History of active TB or listeriosis, or persistent chronic or active infections

          -  Known to have immune deficiency or is immunocompromised

          -  Clinically significant abnormal laboratory test results

          -  Erythrodermic psoriasis or generalized pustular psoriasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2008</study_first_submitted>
  <study_first_submitted_qc>March 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2008</study_first_posted>
  <last_update_submitted>March 26, 2008</last_update_submitted>
  <last_update_submitted_qc>March 26, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2008</last_update_posted>
  <responsible_party>
    <name_title>Beverly Paperiello / Director, Clinical Program Management</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

